The phase 3 TRAILBLAZER-ALZ trial indicated a significant clinical improvement at 76 weeks, showing efficacy in patients with early symptomatic Alzheimer’s disease and confirmed amyloid and tau pathology [31]. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.